Truist Securities has reduced its price target for Boston Scientific Corporation (BSX) to $92 from $95. The firm has maintained its Buy rating on the medical device company's stock.

Key Takeaways

• Truist Securities lowered its price target for Boston Scientific to $92.
• The firm's rating for Boston Scientific remains Buy.

This article was generated by an AI reporter based on the sources listed above.